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Overview	  
 NIH	  research	  management	  drivers	  and	  goals	  
 NIH	  reporIng	  system:	  eSPA	  
 eSPA	  analysis	  case	  studies	  
Managing	  Research	  at	  NIH:	  
Accountability	  Programs	  
•  US	  Office	  of	  Management	  and	  Budget	  
Performance	  Assessment	  RaIng	  Tool	  
•  NIH	  Research	  CondiIon	  and	  Disease	  Coding	  
•  NIH	  PubMed	  Central	  Public	  Access	  Policy	  
•  NIH	  Conflict	  of	  Interest	  ReporIng	  
•  clinicaltrials.gov	  
•  Fed-­‐wide	  STAR	  Metrics	  IniIaIve	  
3	  
Driving	  Forces	  on	  Research	  Management:	  
Na8onal	  Ins8tutes	  of	  Health	  Perspec8ve	  
•  Improve	  programmaIc	  decision	  making	  
•  Increase	  efficiency	  and	  frequency	  of	  porWolio	  
evaluaIon	  efforts	  	  
•  Improve	  transparency	  and	  accountability	  of	  
reporIng	  and	  programmaIc	  decision	  processes	  
•  Demonstrate	  impact	  of	  funding	  on	  public	  health	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eSPA	  is	  a	  Web-­‐based	  
analyIcs	  system	  based	  
on	  linked	  scienIfic	  
databases	  that	  provides	  
quanItaIve	  
informaIon	  for	  NIH	  
staff	  managing	  research	  
porWolios.	  	  
From	  NIAID	  to	  NIH	  
•  April	  2007:	  eSPA	  Pilot	  project	  iniIated	  in	  by	  the	  
NaIonal	  InsItute	  of	  Allergy	  and	  InfecIous	  Disease	  
(NIAID)	  
•  November	  2007:	  ProducIon	  version	  launched	  by	  
NIAID	  
•  March	  2008:	  First	  NIAID	  users	  
•  September	  2008:	  eSPA	  opened	  to	  users	  across	  NIH	  
•  May	  2011:	  There	  are	  over	  1200	  users	  across	  NIH	  
Indicator	   Quan8ta8ve	  Metric	  
Produc8vity	   Publica8ons	  
Quality	   Cita8ons	  	  
Economic	  Impact	   Patent	  Applica8ons,	  	  Issued	  Patents	  
Mission	  Impact	   FDA	  Approved	  Drugs,	  Treatment	  Guidelines	  
Knowledge	  Flow	   Co-­‐authors,	  network	  density,	  centrality	  
Vitality	   Cita8on	  	  velocity	  
eSPA	  Indicators	  
Tested	  automaIon	  of	  research	  impact	  metrics	  for	  the	  
NIH,	  an	  agency	  with	  a	  public	  health	  mission	  and	  a	  
porWolio	  containing	  basic	  and	  applied	  research	  
	  
eSPA	  Indicator	  Data	  Sources	  
Data	  Source	   Processing	  
NIH	  IMPAC	  II	   Grant	  awards	  grouped	  into	  “projects”	  through	  common	  grant	  number	  
InsItute/Center	  (IC)	  abbreviaIon,	  acIvity	  group	  code,	  and	  serial	  number.	  
Medline	  Ar8cles	   ArIcles	  were	  matched	  to	  porWolio	  projects	  based	  on	  Grant	  Numbers	  
included	  in	  Medline	  XML	  data	  feed	  in	  the	  tagged	  field	  for	  acknowledgments.	  	  
Thomson	  Reuters	  
Web	  of	  Science	  
CitaIon	  and	  reference	  counts	  for	  arIcles	  were	  linked	  to	  retrieved	  Medline	  
publicaIons	  based	  on	  combinaIon	  of	  arIcle	  Itle,	  author	  name(s),	  journal	  




Journal	  Impact	  Factors	  linked	  through	  journal	  ISSN,	  Itle,	  and	  publicaIon	  year	  
to	  Medline	  arIcles.	  	  	  
US	  PTO	  Patent	  
Applica8ons	  and	  
Issued	  Patents	  
Published	  patent	  applicaIons	  matched	  to	  porWolio	  projects	  on	  basis	  of	  Grant	  
Numbers	  reported	  within	  the	  “Government	  Interests”	  US	  PTO	  text	  data	  field.	  
FDA	  Electronic	  
Orange	  Book	  
FDA-­‐approved	  drug	  products	  dataset	  contains	  shared	  idenIfier	  in	  an	  
included	  patents	  dataset.	  	  IdenIfied	  patents	  were	  linked	  by	  patent	  number	  
to	  data	  sources	  from	  US	  PTO	  that	  in	  turn	  were	  linked	  to	  grants.	  
eSPA	  Capabili8es	  
•  Faceted	  analyIc	  project	  search	  
•  Build	  and	  share	  project	  porWolios	  
•  Workflow	  for	  group-­‐level	  content	  review	  
•  VisualizaIons	  to	  support	  search	  and	  analyses:	  charts,	  
maps,	  trends,	  scaker	  plots	  
•  Comparisons	  
•  Alerts	  for	  changes	  and	  new	  projects	  
•  Tools	  to	  facilitate	  informaIon	  sharing	  
•  Custom	  analysis	  support	  
	  
eSPA	  Analysis	  Case	  Studies	  
1.  NIH	  Type	  1	  Diabetes	  research	  program	  output	  
analysis	  used	  to	  support	  Congressional	  reporIng	  on	  
program	  impact	  
2.  NIH	  HIV	  research	  porWolio	  content	  analysis	  used	  to	  
focus	  a	  program	  iniIaIve	  
3.  Cost	  and	  outcomes	  analysis	  of	  NIH-­‐sponsored	  select	  
agents	  research	  to	  assess	  impact	  of	  program	  policy	  
1.	  Evalua)on	  of	  NIDDK	  Statutory	  Funding	  
Program	  for	  Type	  1	  Diabetes	  Research	  
•  NIDDK	  used	  eSPA	  back-­‐end	  databases	  to	  collect	  	  publicaIons,	  
number	  of	  citaIons,	  patent	  applicaIons	  and	  grants.	  Found	  1,150	  
unique	  publicaIons,	  19	  patent	  applicaIons,	  and	  12	  patent	  grants.	  
•  Validated	  results	  vs.	  earlier	  manual	  study.	  
•  Also	  analyzed	  clinical	  research	  acIvity,	  proposal	  resubmission	  
and	  award,	  and	  involvement	  of	  new	  invesIgators	  	  
•  Compared	  outcomes	  to	  a	  control	  group	  with	  146,665	  NIH	  
projects	  awarded	  and	  acIve	  during	  the	  same	  Ime	  frame.	  
•  Data	  used	  in	  the	  NIDDK	  	  2010	  Progress	  Report	  to	  the	  US	  Congress	  
•  The	  process	  automa8on	  that	  eSPA	  provided	  allowed	  NIDDK	  to	  
substan8ally	  shorten	  analysis	  8me	  
2.	  NIAID	  HIV	  Vaccine	  Immunology	  
Research	  Collabora)on	  
•  Development	  of	  a	  prevenIve	  vaccine	  for	  HIV/AIDS	  is	  
one	  of	  the	  highest	  prioriIes	  of	  NIAID	  
•  In	  2005,	  NIAID	  launched	  an	  internal	  collaboraIon	  
with	  the	  aim	  to	  foster	  new	  research	  on	  inducIon	  of	  
broadly	  neutralizing	  HIV	  anIbodies.	  	  	  
•  eSPA	  allowed	  for	  collabora8ve	  analysis	  of	  por>olio	  
content	  and	  enabled	  mul8ple	  analyses	  to	  be	  
applied	  to	  each	  research	  por>olio	  
HIV	  Vaccine	  Collabora8on:	  
Findings	  
The	  relaIonship	  between	  number	  of	  citaIons	  and	  total	  
publicaIons	  was	  used	  to	  help	  assess	  project	  producIvity,	  and	  
permiked	  the	  idenIficaIon	  of	  key	  advances.	  
	  
HIV	  Vaccine	  Collabora8on:	  	  
Policy	  Implica8ons	  
•  NIAID	  took	  acIon	  to	  develop	  collaboraIons	  between	  
basic	  immunologists	  and	  HIV	  researchers	  by	  holding	  
seminars	  and	  colloquia	  at	  naIonal	  meeIngs	  to	  
inform	  the	  scienIfic	  community	  of	  the	  importance	  of	  
and	  NIH	  support	  for	  collaboraIve	  projects.	  
•  NIAID	  developed	  funding	  requests	  for	  applicaIons	  
(RFAs)	  for	  compeIIve	  supplements	  for	  exisIng	  
grants	  and	  for	  new	  cooperaIve	  agreements	  in	  
needed	  areas.	  
3.	  Impact	  of	  Research	  Policy	  on	  Select	  
Agents	  Research	  
•  Select	  agents	  are	  biological	  agents	  and	  toxins	  that	  
have	  the	  poten4al	  to	  pose	  a	  severe	  threat	  to	  public,	  
animal,	  or	  plant	  health,	  or	  to	  animal	  or	  plant	  
products.	  	  	  
•  Research	  on	  select	  agents	  is	  Ightly	  regulated	  by	  the	  
USA	  PATRIOT	  Act	  and	  the	  2002	  Bioterrorism	  
Preparedness	  Act	  	  
•  eSPA	  allowed	  NIAID	  to	  test	  the	  impact	  of	  these	  
regula8ons	  on	  research	  performance	  
	  
Select	  Agents:	  	  
Methods	  
•  eSPA	  supported	  definiIon	  of	  porWolios	  by	  project	  
start	  date,	  which	  allowed	  for	  determinaIon	  of	  the	  
effect	  of	  the	  Acts	  on	  cost	  per	  publicaIon.	  	  
•  Two	  sets	  of	  porWolios	  were	  created	  for	  the	  select	  
agents	  Anthrax	  and	  Ebola	  and	  a	  non-­‐select	  agent	  
control	  Kliebsiella:	  
–  An	  established	  inves4gator	  porWolio,	  containing	  projects	  
for	  each	  agent	  with	  a	  start	  date	  prior	  to	  2002	  and	  that	  
conInued	  through	  2008.	  	  
–  A	  new	  inves4gator	  porWolio,	  containing	  projects	  for	  each	  
agent	  with	  a	  start	  date	  aoer	  2002.	  
Select	  Agents:	  	  
Findings	  and	  Policy	  Implica8ons	  
A	  significant	  influx	  of	  new	  research	  projects	  followed	  the	  
passage	  of	  the	  Acts.	  The	  eSPA	  analysis	  found	  that	  the	  cost	  of	  
performing	  select	  agents	  research	  has	  increased	  specifically	  for	  
new	  grants,	  and	  may	  affect	  the	  entry	  of	  new	  researchers	  into	  
the	  field.	  
Conclusions	  and	  Remaining	  Challenges	  
•  The	  eSPA	  project	  has	  clearly	  demonstrated	  the	  
feasibility	  and	  uIlity	  of	  automaIng	  linkages	  between	  
projects	  and	  outputs/outcomes	  
•  In	  addi4on	  to	  those	  indicators	  tested,	  there	  .exist	  
many	  other	  poten4al	  indicators	  of	  interest	  
•  In	  addi4on,	  eSPA	  could	  be	  used	  to	  provide	  validated,	  
organized	  data	  and	  visualiza4ons	  for	  hypothesis-­‐
tes4ng	  of	  indicators	  and	  program	  design	  
Thank	  you!	  
